Towards novel paradigms for cancer therapy

Abstract

Cancer is a complex progressive multistep disorder that results from the accumulation of genetic and epigenetic abnormalities, which lead to the transformation of normal cells into malignant derivatives. Despite enormous progress in the understanding of cancer biology including the decryption of multiple regulatory networks governing cell growth and death, and despite the possibility of analyzing (epi)genetic deregulation at the genome-wide scale, cancertargeted therapy is still the exception. In fact, to date there are still far too few examples of therapies leading to cure; treatment-derived toxicity is a major issue, and cancer remains to be one of the largest causes of death worldwide. The purpose of this review is to discuss the state of the art of cancer therapy with respect to the key issue of any treatment, namely its target selectivity. Therefore, we recapitulate and discuss current concepts and therapies targeting tumorspecific features, including oncofusion proteins, aberrant kinase activities and epigenetic tumor makeup. We analyze strategies designed to induce tumor-selective death such as the use of oncolytic virus, tumoricidal proteins (NS1, Eorf4, apoptin, HAMLET (human a-lactalbumin made lethal to tumor cells)) and activation of signaling pathways involved in tumor surveillance. We emphasize the potential of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) pathway, an essential component of the evolutionary developed defense systems that eradicate malignant cells. Finally, we discuss the necessity of targeting tumor-initiating cells (TICs) to avoid relapse and increase the chances of complete remission, and describe emerging concepts that might provide novel avenues for cancer therapy.

Effective Transgene Constructs to Enhance Gene Therapy with Trichostatin A

“…Other molecules (Bax, Caspase8, and TRIF) that induce apoptosis by activating different pathways should be beneficial for the treatment of various tumors, because each cancer employs various strategies to escape from the host immune surveillance and to gain growth advantages (Liu et al, 2011;Luo et al, 2009;Pavet et al, 2011). As shown in Fig.…”

Autophagy as a mediator of chemotherapy-induced cell death in cancer

“…Targeted therapy, based on specific alterations of cancer cells, is the next frontier in chemotherapy, [1][2][3].…”

New frontiers in promoting tumour cell death: targeting apoptosis, necroptosis and autophagy

“…In pre-clinical studies, the co-administration of TRAIL with chemotherapeutic agents, irradiation, Akt inhibitors or proteasome inhibitors sensitised TRAIL-resistant tumours to cell death (Hetschko et al, 2008;Pavet et al, 2011). The mechanism of sensitisation was unclear but proteasomal inhibitors have been shown to prime tumour cells to die in response to TRAIL by upregulating the DR5 receptor or promoting DISC formation (Koschny et al, 2007;Hetschko et al, 2008).…”